

# BIOTECH SHOWCASE™ 2016

**JANUARY 11-13, 2016**  
SAN FRANCISCO, CA, USA

PARC 55 SAN FRANCISCO - A HILTON HOTEL

## INVESTOR SUMMARY PROFILES OF PRESENTING COMPANIES

Co-produced by

**EBD**  
GROUP

**DEMY**  
COLTON

PARTNERING EXCELLENCE  
**DOMANN**  
RETAINED SEARCH EST. 1988



### COMMITMENT TO GREAT LEADERSHIP

Now, more than ever, Executive and Board leadership are key. Innovative biopharmaceutical and healthcare companies require game changing talent, agile, seasoned executives, who add and create immediate value. Since opening our first office in San Francisco during the industry's infancy, Domann has invested our resources on building winning leadership teams for the Life Sciences.

In today's highly competitive talent environment, it is paramount to be represented by an established firm with a commanding market presence, global reach, and solid reputation of success. Domann's reputation is one of professionalism, integrity, transparency and results.

With over 90% of our business repeat or referral we must be doing something right.  
Domann, executive search that delivers!

[WWW.DOMANN.NET](http://WWW.DOMANN.NET)

**ABIVAX S.A.** (EURONEXT: ABVX)

ABIVAX is an emerging leader in the discovery, development and commercialization of anti-viral therapies and therapeutic vaccines to treat life-threatening infectious diseases. ABIVAX has 2 compounds in clinical trials: ABX464, a first-in-class, long-acting oral small molecule HIV/AIDS therapy; and ABX203, a therapeutic vaccine for immunotherapy of chronic hepatitis B.

**Location:** Paris, Ile-De-France France

**Year Established:** 2013 **Website:** www.abivax.com

**Therapeutic Focus:** Viral diseases representing a high medical need: HIV/AIDS, Chronic Hepatitis B, Dengue, Chikungunya, Ebola and others

**Technology/Target:** NA

**Development Status:** Chronic Hepatitis B therapy: Phase 2b/3; HIV/AIDS therapy: Phase 2a; compounds against Dengue, Chikungunya and Ebola at preclinical stage

**Corporate Partners:** NA

**Funds Raised:** €57.7M raised in IPO as of June 2015

**Presenter:** Hartmut Ehrlich, MD, CEO

---

**Abzena plc** (LSE: ABZA)

Abzena offers a suite of complementary services and technologies through its subsidiaries, PolyTherics, Antitope, PacificGMP and TCRS to enable the development of better biopharmaceuticals which will have a greater chance of reaching the market. Its core areas include immunogenicity assessment, protein engineering, GMP manufacturing and antibody drug conjugates.

**Location:** Cambridge, England United Kingdom

**Year Established:** 2014 **Website:** www.abzena.com

**Therapeutic Focus:** NA

**Technology/Target:** Immunogenicity assessment, humanisation of antibodies, deimmunisation of proteins, development of manufacturing cell lines, antibody drug conjugation, manufacturing for clinical trials

**Development Status:** NA

**Corporate Partners:** None

**Funds Raised:** Approx. \$33M raised in July 2014 in conjunction with an IPO

**Presenter:** Donna Hackett, Vice President IP, Legal and Commercial Operations

## Xcovery

Developing X-396, for anaplastic lymphoma kinase (ALK) positive NSCLC, currently in Phase 2, with FDA established treatment-naïve Phase 3 development pathway to approval. X-396 is a molecularly-targeted small molecule discovered by Xcovery, which invented and owns worldwide rights, except for China.

**Location:** Needham, Massachusetts United States

**Year Established:** 2006 **Website:** www.xcovery.com

**Therapeutic Focus:** Oncology

**Technology/Target:** X-396 provides 3-10x greater potency than competitive agents with increased potential to impact brain metastases and overcome resistance

**Development Status:** Phase 2 for ALK+ NSCLC

**Corporate Partners:** Betta Pharmaceuticals

**Funds Raised:** \$20M in 2014

**Presenter:** Michael Webb, President & CEO

## XyloCor Therapeutics, Inc.

Clinical-stage biotechnology company developing gene therapies for serious cardiovascular disease. Lead program XC001, is a phase I/II angiogenic gene therapy for diffuse coronary artery disease. Pipeline includes XC002, a preclinical heart repair gene therapy to reprogram cardiac scar tissue, caused by myocardial injury, into beating heart muscle.

**Location:** New York, New York United States

**Year Established:** 2013 **Website:** www.xylocor.com

**Therapeutic Focus:** Cardiovascular; XC001: Angiogenic gene therapy for diffuse coronary artery disease; XC002: heart repair gene therapy for myocardial injury

**Technology/Target:** XC001: Angiogenic gene therapy for diffuse coronary artery disease; XC002: heart repair gene therapy for myocardial injury

**Development Status:** Lead product, XC001, approved IND (FDA, NIH, RAC, IRB) for Phase 1/2 trial Initiation; Second program, XC002, preclinical stage-of-development

**Corporate Partners:** NA

**Funds Raised:** NA

**Presenter:** Todd Rosengart, Founder & Interim CEO

## Zenith Epigenetics Corp.

Zenith Epigenetics Corp. is a preclinical biotechnology company developing best in class bromodomain (BET) inhibitors for the treatment of cancer and autoimmune disorders in targeted patient populations with significant unmet medical need. The company's cutting edge epigenetic platform of innovative biology and chemistry has generated differentiated, potent and selective BET inhibitors.

**Location:** San Francisco, California United States

**Year Established:** 2013 **Website:** www.zenithepigenetics.com

**Therapeutic Focus:** oncology, autoimmune

**Technology/Target:** Lead product is a pan selective BET inhibitor being developed for hematological malignancies and solid tumors; IND planned in 1H15

**Development Status:** Preclinical

**Corporate Partners:** NA

**Funds Raised:** NA

**Presenter:** Donald McCaffrey, President & CEO

### Cancelled presentations as of Dec. 30, 2015

7 Hill Pharma  
NVS Technologies  
Provista Diagnostics, Inc.  
Soligenix, Inc.

#### NOTE:

Please refer to the Conference Update Sheet distributed daily at the Registration Area for Summaries of Presenting Companies that missed the submission deadline for this publication.

The information contained in this book is current as of December 30, 2015 and was obtained through sources believed to be reliable, including information provided by the company representatives and company web sites. Information was edited to fit into the format of this book.

Demy-Colton Life Science Advisors and EBD Group, the organizers of Biotech Showcase™, Medtech Showcase and Digital Health Showcase do not guarantee that this information is complete or correct, nor do they warrant the information for a particular purpose. The organizers do not underwrite securities or make markets in them. The presenting companies may participate in other meetings produced by the organizers.